The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group.

TY - JOUR

T1 - The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group.

AU - Terpos, E

AU - Dimopoulos, M A

AU - Sezer, Orhan

AU - Roodman, D

AU - Abildgaard, N

AU - Vescio, R

AU - Tosi, P

AU - Garcia-Sanz, R

AU - Davies, F

AU - Chanan-Khan, A

AU - Palumbo, A

AU - Sonneveld, P

AU - Drake, M T

AU - Harousseau, J-L

AU - Anderson, K C

AU - Durie, B G M

AU - Group, International Myeloma Working

PY - 2010

Y1 - 2010

N2 - Lytic bone disease is a frequent complication of multiple myeloma (MM). Lytic lesions rarely heal and X-rays are of limited value in monitoring bone destruction during anti-myeloma or anti-resorptive treatment. Biochemical markers of bone resorption (amino- and carboxy-terminal cross-linking telopeptide of type I collagen (NTX and CTX, respectively) or CTX generated by matrix metalloproteinases (ICTP)) and bone formation provide information on bone dynamics and reflect disease activity in bone. These markers have been investigated as tools for evaluating the extent of bone disease, risk of skeletal morbidity and response to anti-resorptive treatment in MM. Urinary NTX, serum CTX and serum ICTP are elevated in myeloma patients with osteolytic lesions and correlate with advanced disease stage. Furthermore, urinary NTX and serum ICTP correlate with risk for skeletal complications, disease progression and overall survival. Bone markers have also been used for the early diagnosis of bone lesions. This International Myeloma Working Group report summarizes the existing data for the role of bone markers in assessing the extent of MM bone disease and in monitoring bone turnover during anti-myeloma therapies and provides information on novel markers that may be of particular interest in the near future.

AB - Lytic bone disease is a frequent complication of multiple myeloma (MM). Lytic lesions rarely heal and X-rays are of limited value in monitoring bone destruction during anti-myeloma or anti-resorptive treatment. Biochemical markers of bone resorption (amino- and carboxy-terminal cross-linking telopeptide of type I collagen (NTX and CTX, respectively) or CTX generated by matrix metalloproteinases (ICTP)) and bone formation provide information on bone dynamics and reflect disease activity in bone. These markers have been investigated as tools for evaluating the extent of bone disease, risk of skeletal morbidity and response to anti-resorptive treatment in MM. Urinary NTX, serum CTX and serum ICTP are elevated in myeloma patients with osteolytic lesions and correlate with advanced disease stage. Furthermore, urinary NTX and serum ICTP correlate with risk for skeletal complications, disease progression and overall survival. Bone markers have also been used for the early diagnosis of bone lesions. This International Myeloma Working Group report summarizes the existing data for the role of bone markers in assessing the extent of MM bone disease and in monitoring bone turnover during anti-myeloma therapies and provides information on novel markers that may be of particular interest in the near future.

KW - Humans

KW - Biological Markers metabolism

KW - Bone Remodeling

KW - International Agencies

KW - Multiple Myeloma metabolism

KW - Humans

KW - Biological Markers metabolism

KW - Bone Remodeling

KW - International Agencies

KW - Multiple Myeloma metabolism

M3 - SCORING: Zeitschriftenaufsatz

VL - 24

SP - 1700

EP - 1712

JO - LEUKEMIA

JF - LEUKEMIA

SN - 0887-6924

IS - 10

M1 - 10

ER -